Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)
Status:
Completed
Trial end date:
2018-11-14
Target enrollment:
Participant gender:
Summary
Study to evaluate the efficacy, safety and tolerability of GSP 301 nasal spray (NS) compared
with placebo NS in pediatric subjects (aged 6 to under 12 years) with Seasonal Allergic
Rhinitis (SAR).